![Flavia Borellini](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Flavia Borellini
Direktor/Vorstandsmitglied bei
REVOLUTION MEDICINES, INC.
Vermögen: 4 Mio $ am 31.05.2026
Profil
Flavia Borellini currently serves as Independent Director at Cantargia AB since 2020, Independent Director at Revolution Medicines, Inc. since 2021, Director at Kartos Therapeutics, Inc. since 2018, and as a Member of Roche Group.
Former roles include Chief Executive Officer at Acerta Pharma BV from 2016 to 2019, Independent Director at Viracta Therapeutics, Inc. from 2021 to 2025, VP-Global Product & Portfolio Strategy at AstraZeneca PLC from 2018 to 2020, and Vice President-Program Leadership at Onyx Pharmaceuticals, Inc. from 2012 to 2013.
Education includes a doctorate from Università degli Studi di Modena e Reggio Emilia.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 18.06.2026 | 26.215 ( 0,01 % ) | 4 Mio $ | 31.05.2026 |
Aktive Positionen von Flavia Borellini
| Unternehmen | Position | Beginn |
|---|---|---|
| REVOLUTION MEDICINES, INC. | Direktor/Vorstandsmitglied | 22.06.2021 |
| CANTARGIA AB | Direktor/Vorstandsmitglied | 01.10.2020 |
Kartos Therapeutics, Inc.
 Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company | Direktor/Vorstandsmitglied | 01.02.2018 |
Roche Group
 Roche Group Real Estate DevelopmentFinance Manages real estate properties | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Flavia Borellini
| Unternehmen | Position | Ende |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 05.02.2025 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01.01.2020 |
Acerta Pharma BV
 Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Vorstandsvorsitzender | 01.02.2019 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Corporate Officer/Principal | 01.10.2013 |
Ausbildung von Flavia Borellini
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
42
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
Roche Group
Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
Università degli Studi di Modena e Reggio Emilia
 Università degli Studi di Modena e Reggio Emilia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cantargia AB
 Cantargia AB Pharmaceuticals: MajorHealth Technology Creates and develops antibody therapeutics for the treatment of leukemia | Health Technology |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Health Technology |
Revolution Medicines, Inc.
 Revolution Medicines, Inc. Pharmaceuticals: OtherHealth Technology Develops new therapies derived from natural products | Health Technology |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company | Health Technology |
Viracta Therapeutics, Inc.
 Viracta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for virus-associated cancers | Health Technology |
